Ablation with immunotherapy and chemo before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new approach for people with early-stage lung cancer that can be removed with surgery. Before surgery, patients receive a treatment called cryo-thermal ablation to freeze and heat the tumor, along with an immunotherapy drug (toripalimab) and chemotherapy. The goal is to see if this combination shrinks tumors and improves outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer that is stage IB to IIIB and can be removed with surgery.
- You are between 18 and 80 years old.
- You are generally well enough to have treatment, with a good performance status (ECOG 0-1).
- Your lung function is good enough for both the study treatment and surgery.
- You have not had previous treatment for this lung cancer.
- You do not have certain genetic changes in your tumor (like EGFR, ALK, ROS1, KRAS G12C, etc.) that have targeted therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of an immunotherapy drug (sintilimab), chemotherapy, and a procedure called cryoablation (freezing the tumor) for people with a type of lung cancer called non-small cell lung cancer that has spread or come back. The goal is to see if this combination is safe and effective.
This trial tests whether combining a tumor-destroying procedure (ablation) with immunotherapy (tislelizumab) and chemotherapy before surgery can improve outcomes for people with stage II-IIIB non-small cell lung cancer. The goal is to shrink the tumor and boost the immune system to fight the cancer more effectively.
This trial tests a treatment for early-stage lung cancer (stage I-IIA) that uses extreme cold to freeze and destroy the tumor, called cryoablation. Some patients will also receive an immunotherapy drug called serplulimab, which helps the immune system fight the cancer, to see if adding it improves outcomes.
This trial tests a combination of a drug that helps your immune system fight cancer (serplulimab) and a procedure that freezes and destroys cancer cells (cryoablation) for people with early-stage non-small cell lung cancer who cannot or choose not to have surgery or radiation. The goal is to see if this combination is safe and effective.
Hear when a new Carcinoma, Non-Small-Cell Lung (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.